Landscape → Infectious Disease

C. difficile Clinical Trial Landscape

Data updated: May 20, 2026

175 clinical trials tracked since 2008

C. difficile is being studied across 175 clinical trials registered since 2008, with 21 programs currently active. The competitive pipeline includes 6 active Phase 3 trials, 11 active Phase 2 trials, and 9 active Phase 1 trials. Top industry sponsors include AstraZeneca, Vedanta Biosciences, Inc., Acurx Pharmaceuticals Inc..

21 active

175 total (since 2008)

Phase 1 Active

41 total

Phase 2 Active

82 total

Phase 3 Active

45 total

Phase 4 Active

27 total

Top Industry Sponsors

Sorted by active Active Done Failed

AstraZeneca 1 1 0

Vedanta Biosciences, Inc. 1 1 0

Acurx Pharmaceuticals Inc. 1 1 0

Theriva Biologics, Inc. 1 1 0

Lumen Bioscience, Inc. 1 0 0

+ 10 more sponsors — see full table below

Featured Phase 3 Trials

NCT07458984 RECRUITING

FMT Capsules for rCDI

Helsinki University Central Hospital n=76

NCT06237452 RECRUITING

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

Vedanta Biosciences, Inc. n=852

NCT05330182 RECRUITING

LMN-201 for Prevention of C. Difficile Infection Recurrence

Lumen Bioscience, Inc. n=375

NCT07221370 RECRUITING

Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients

Riverside University Health System Medical Center n=176

NCT06979609 RECRUITING

Secondary Prevention of Clostridioides Difficile Using Vancomycin

McGill University Health Centre/Research Institute of the McGill University Health Centre n=300

+ 40 more Phase 3 trials — see full database below

C. difficile — Trials Started by Year (last 10 years)

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

TheraRadar.com

Full Trial Database

Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.

Top Sponsors (all-time)

AstraZeneca

Vedanta Biosciences, Inc.

Acurx Pharmaceuticals Inc.

Theriva Biologics, Inc.

Lumen Bioscience, Inc.

Pfizer

Sanofi

Actelion

Rebiotix Inc.

Merck

Active Trials by Phase

Phase 1

Phase 2

Phase 3

Phase 4

Enrollment Size Distribution

1-50

51-200

201-500

501-1k

1k+

All Industry Sponsors

Sorted by active Active Done Failed

AstraZeneca 1 1 0

Vedanta Biosciences, Inc. 1 1 0

Acurx Pharmaceuticals Inc. 1 1 0

Theriva Biologics, Inc. 1 1 0

Lumen Bioscience, Inc. 1 0 0

Pfizer 0 8 0

Sanofi 0 3 2

Actelion 0 4 1

Rebiotix Inc. 0 5 0

Merck 0 5 0

Summit Therapeutics 0 3 1

Seres Therapeutics, Inc. 0 4 0

Astellas Pharma Europe Ltd. 0 2 1

Finch Research and Development LLC. 0 2 1

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 0 3 0

NCT07458984 RECRUITING

FMT Capsules for rCDI

Helsinki University Central Hospital n=76

NCT06237452 RECRUITING

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

Vedanta Biosciences, Inc. n=852

NCT05330182 RECRUITING

LMN-201 for Prevention of C. Difficile Infection Recurrence

Lumen Bioscience, Inc. n=375

NCT07221370 RECRUITING

Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients

Riverside University Health System Medical Center n=176

NCT06979609 RECRUITING

Secondary Prevention of Clostridioides Difficile Using Vancomycin

McGill University Health Centre/Research Institute of the McGill University Health Centre n=300

NCT05266807 RECRUITING

Fecal Microbiota Transplantation in Clostridioides Difficile Infection First Episode and First Recurrence

Benoit Guery n=220

NCT05831189 COMPLETED

A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection

Ferring Pharmaceuticals n=41

NCT04138706 COMPLETED

Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection

McGill University Health Centre/Research Institute of the McGill University Health Centre n=263

NCT03105479 TERMINATED

Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD)

Actelion n=1

NCT05201079 COMPLETED

Primary or Recurrent Clostridioides Difficile Infection Treatment With Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin

Mikrobiomik Healthcare Company S.L. n=93

NCT01983683 COMPLETED

Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea

Actelion n=631

NCT01987895 COMPLETED

Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea

Actelion n=632

NCT05320068 COMPLETED

Oral Vancomycin Vs Placebo in the Prevention of Recurrence of Clostridioides Difficile's Infection

Julia Orígüen n=24

NCT02218372 COMPLETED

A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

Astellas Pharma Europe B.V. n=148

NCT02179658 COMPLETED

A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

Astellas Pharma Inc n=210

NCT03796650 TERMINATED

Fecal Transplantation for Primary Clostridium Difficile Infection

Oslo University Hospital n=104

NCT03931941 COMPLETED

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS)

Rebiotix Inc. n=793

NCT03244644 COMPLETED

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)

Rebiotix Inc. n=320

NCT03005379 TERMINATED

Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH)

VA Office of Research and Development n=153

NCT03918629 COMPLETED

Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study

Pfizer n=1,994

NCT05153499 TERMINATED

A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4)

Finch Research and Development LLC. n=19

NCT04802837 TERMINATED

Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects

Summit Therapeutics n=2

NCT03182907 COMPLETED

Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)

Merck Sharp & Dohme LLC n=148

NCT03183128 COMPLETED

ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection

Seres Therapeutics, Inc. n=182

NCT03183141 COMPLETED

ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection

Seres Therapeutics, Inc. n=263

NCT02395848 TERMINATED

Efficacy of 30-day Duration of Fidaxomicin for Recurrent C. Difficile Infection

McMaster University n=31

NCT03595553 COMPLETED

Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection

Summit Therapeutics n=759

NCT03090191 COMPLETED

Clostridium Difficile Vaccine Efficacy Trial

Pfizer n=17,535

NCT03579459 COMPLETED

Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age

Pfizer n=1,317

NCT01598311 COMPLETED

A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) n=608

NCT02801656 WITHDRAWN

Fecal Microbiota Transplantation for Primary Clostridium Difficile Diarrhea

Memorial University of Newfoundland

NCT01887912 TERMINATED

Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection

Sanofi Pasteur, a Sanofi Company n=9,302

NCT02301000 TERMINATED

IMT for Primary Clostridium Difficile Infection

Oslo University Hospital n=21

NCT02254811 COMPLETED

FMT Delivered by Capsule Versus Colonoscopy for Recurrent C. Diff

University of Alberta n=116

NCT02743234 COMPLETED

Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection

University of Aarhus n=64

NCT01597505 COMPLETED

Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) n=606

NCT01691248 COMPLETED

Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001)

Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) n=611

NCT01241552 COMPLETED

A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)

Merck Sharp & Dohme LLC n=1,452

NCT01513239 COMPLETED

A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)

Merck Sharp & Dohme LLC n=1,203

NCT01143272 TERMINATED

Probiotic Saccharomyces Boulardii for the Prevention of Antibiotic-associated Diarrhoea

Bernhard Nocht Institute for Tropical Medicine n=477

NCT01202630 SUSPENDED

BIO-K+ CL1285 for Prevention of Recurrent Clostridium Difficile Infection

Bio-K Plus International Inc. n=140

NCT01226992 TERMINATED

Oral Vancomycin Followed by Fecal Transplant Versus Tapering Oral Vancomycin

University Health Network, Toronto n=81

NCT01295918 COMPLETED

Probiotic Lactobacillus Reuteri to Prevent Antibiotic-associated Diarrhea and Clostridium Difficile-related Infections in Hospitalized Children

St Marina University Hospital, Varna, Bulgaria n=100

NCT00747071 WITHDRAWN

Safety and Validation of Efficacy of Oral Administration of the Food Additive Colostrum Derived Anti Clostridium Difficile Antibodies

Hadassah Medical Organization

NCT00958308 COMPLETED

Efficacy and Safety Study in the Prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridium Difficile-Associated Diarrhea (CDAD) in Hospitalized Adult Patients Exposed to Nosocomial Infection

Bio-K Plus International Inc. n=255

NCT07285213 RECRUITING

Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody

AstraZeneca

NCT07513285 NOT YET RECRUITING

ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection

Acurx Pharmaceuticals Inc.

NCT06071312 RECRUITING

FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

NCT04692181 ACTIVE NOT RECRUITING

SYN-004 Safety and Tolerability in Allo-HCT Subjects

Theriva Biologics, Inc.

NCT06306014 RECRUITING

Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients

Hospices Civils de Lyon

NCT02127398 RECRUITING

Stool Transplants to Treat Refractory Clostridium Difficile Colitis

Duke University

NCT06948461 NOT YET RECRUITING

A Flexible Clinical Trial to Test if Freeze-dried Fecal Microbiota Therapy Helps Treat Diarrhea-predominant Irritable Bowel Syndrome or Prevent Recurring C. Difficile Infections.

PharmaPlanter Technologies Inc

NCT04305769 RECRUITING

Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)

University of Virginia

NCT03030248 COMPLETED

Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients

Medical College of Wisconsin

NCT04781387 COMPLETED

Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection

Crestone, Inc

NCT07496502 COMPLETED

Effect of Oral Microbiota on MDRO Decolonization

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

NCT05304715 COMPLETED

Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection

Hellenic Institute for the Study of Sepsis

NCT03829475 COMPLETED

ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI

Brigham and Women's Hospital

NCT06536465 TERMINATED

The Clostridioides Difficile Trial of REC-3964

Recursion Pharmaceuticals Inc.

NCT03462459 COMPLETED

Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection

University of Wisconsin, Madison

NCT03589768 COMPLETED

Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04247542 COMPLETED

ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection

Acurx Pharmaceuticals Inc.

NCT03617445 TERMINATED

Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients

University of Wisconsin, Madison

NCT03806803 COMPLETED

Multicentre Blinded Comparison of Lyophilized Sterile Fecal Filtrate to Lyophilized Fecal Microbiota Transplant in Recurrent Clostridioides Difficile Infection

University of Alberta

NCT02318992 COMPLETED

Fresh, Frozen or Lyophilized Fecal Microbiota Transplantation for Multiple Recurrent C. Difficile Associated Diarrhea

The University of Texas Health Science Center, Houston

NCT03973697 TERMINATED

Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection

University of Pennsylvania

NCT03970200 TERMINATED

Penn Microbiome Therapy (PMT) for Severe-Clostridium Difficile Infection (CDI)

University of Pennsylvania

NCT03788434 COMPLETED

Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection

Vedanta Biosciences, Inc.

NCT02255305 TERMINATED

FMT Versus Antimicrobials for Initial Treatment of Recurrent CDI

Endeavor Health

NCT03760484 TERMINATED

Fecal Microbiota Transplant (FMT) Plus Fidaxomicin for Severe or Fulminant Clostridium Difficile Infection

University of Alberta

NCT03617172 TERMINATED

PROCLAIM -- Misoprostol in the Prevention of Recurrent CDI Prevent Recurrence of Clostridium Difficile Infection With Misoprostol

Vanderbilt University Medical Center

NCT03110133 COMPLETED

Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff

Finch Research and Development LLC.

NCT03497806 COMPLETED

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

Finch Research and Development LLC.

NCT02053350 TERMINATED

Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection

University of Virginia

NCT02707198 TERMINATED

Prevention of Clostridium Difficile-associated Diarrhea by Daily Intake of Kefir

St. Luke's Hospital of Duluth

NCT03795233 TERMINATED

Fecal Microbiota Transplant for Primary CDI

Boston Medical Center

NCT02394275 TERMINATED

A Prospective Trial of Frozen-and-Thawed Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection

McMaster University

NCT01259726 COMPLETED

Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection

Shire

NCT01398969 COMPLETED

Multi-Centre Trial of Fresh vs. Frozen-and-Thawed FMT for Recurrent CDI

McMaster University

NCT02589847 COMPLETED

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

Rebiotix Inc.

NCT03621657 COMPLETED

The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation

University of Wisconsin, Madison

NCT02561195 COMPLETED

A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years

Pfizer

NCT02403622 TERMINATED

Safety of FMT: OpenBiome Outcomes and Longitudinal Follow-up (STOOL) for Recurrent Clostridium Difficile Infection

Microbiome Health Research Institute

NCT03643887 WITHDRAWN

Phase II Trial of Fecal Microbiota Transplant (FMT) for VRE and CRE Patients

University of Wisconsin, Madison

NCT03106844 COMPLETED

The ICON Study: Outcomes After FMT for Patients With IBD and CDI

Brigham and Women's Hospital

NCT04729790 WITHDRAWN

Randomized Clinical Trial of Standard FMT Treatments

The University of Texas Health Science Center, Houston

NCT02299570 COMPLETED

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

Rebiotix Inc.

NCT01232595 COMPLETED

Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections

Novartis Pharmaceuticals

NCT02148601 COMPLETED

Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection

Catholic University of the Sacred Heart

NCT03824795 COMPLETED

Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD

MGB Biopharma Limited

NCT03298048 TERMINATED

Dose Ranging Study of the Safety and Efficacy of Orally Administered Lyophilized Fecal Microbiota Product (PRIM-DJ2727) for the Treatment of Recurrent Clostridium Difficile Infection (CDI)

The University of Texas Health Science Center, Houston

NCT03353506 COMPLETED

Lyophilized Fecal Transplant vs Lyophilized Fecal Filtrate in Recurrent C Diff Infection

Dina Kao

NCT03065374 TERMINATED

Treatment for Clostridium-difficile Infection With IMM529

Immuron Ltd.

NCT01925417 COMPLETED

Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea

Rebiotix Inc.

NCT02449174 COMPLETED

Fecal Microbiota Transplantation to Treat Recurrent C. Difficile Associated Diarrhea Via Retention Enema or Oral Route

The University of Texas Health Science Center, Houston

NCT02857582 COMPLETED

Transplantation of Cultured Gut Microflora to Repeat Antibiotic-induced Diarrhea Due to Clostridium Difficile

Per Hellström

NCT02563106 COMPLETED

A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI

Theriva Biologics, Inc.

NCT01591863 COMPLETED

Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

NCT01085591 COMPLETED

Study of CB-183,315 in Participants With Clostridium Difficile Infection

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

NCT02437487 COMPLETED

SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)

Seres Therapeutics, Inc.

NCT01230957 COMPLETED

Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults

Sanofi Pasteur, a Sanofi Company

NCT01896830 COMPLETED

Study of a Candidate Clostridium Difficile Toxoid Vaccine in Healthy Adult Subjects Aged 40 to 75 Years in Japan

Sanofi Pasteur, a Sanofi Company

NCT03427229 COMPLETED

Fecal Microbiota Transplantation for Severe Clostridium Difficile Infection

Catholic University of the Sacred Heart

NCT02465463 COMPLETED

Early FMT for C.Difficile

Emory University

NCT02784002 COMPLETED

A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)

Summit Therapeutics

NCT01222702 COMPLETED

Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)

Actelion

NCT02316470 COMPLETED

Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study

Valneva Austria GmbH

NCT02117570 COMPLETED

A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.

Pfizer

NCT02092935 COMPLETED

A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)

Summit Therapeutics

NCT01972334 COMPLETED

Stool Transplant in Pediatric Patients With Recurring C. Difficile Infection

MemorialCare Health System

NCT02502682 COMPLETED

Chlorhexidine Bathing Effect on Clostridium Difficile Rates

Jared Brooks

NCT01475942 COMPLETED

Probiotic Intervention With Elderly Subjects

Danisco

NCT01680874 COMPLETED

Probiotics for Clostridium Difficile Infection in Older Adults

University of Wisconsin, Madison

NCT01048567 TERMINATED

Efficacy and Safety of Lactobacillus Acidophilus/Rhamnosus Combination for the Prevention of Antibiotic-associated Diarrhea in the Elderly

Vancouver Island Health Authority

NCT01077245 WITHDRAWN

Safety and Clinical Effectiveness of Oral Probiotic MIYA-BM to Prevent Recurrent Clostridium Difficile Infections

Osel, Inc.

NCT00772343 COMPLETED

Study of a Clostridium Difficile Toxoid Vaccine (ACAM-CDIFF™) in Subjects With Clostridium Difficile Infection

Sanofi Pasteur, a Sanofi Company

NCT01559545 COMPLETED

A Safety, Tolerability and Pharmacokinetic Study of Two Formulations of Metronidazole Versus Immediate Release Metronidazole in Patient With C. Difficile Colitis

Dr. Reddy's Laboratories Limited

NCT01570634 TERMINATED

Proof-of-Concept, Calcium Aluminosilicate Anti-Diarrheal (CASAD) for Treatment of Clostridium Difficile Infection

Salient Pharmaceuticals Incorporated

NCT07401680 RECRUITING

Fecal Microbiota Transplantation in an Expanded Ulcerative Colitis Population

University of Alberta

NCT02636517 ENROLLING BY INVITATION

Fecal Microbiome Transplant

Judith Kelsen

NCT06370884 RECRUITING

Intestinal Microbiota Transplantation in Patients Undergoing Colon Resection

University of Minnesota

NCT05852587 NOT YET RECRUITING

Xylitol Use for Decolonization of C. Difficile in Patients With IBD

Brigham and Women's Hospital

NCT06692179 RECRUITING

An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of A Suspension of Freeze-dried Microbiota In Patients Undergoing Colon Resection

University of Minnesota

NCT01868373 ENROLLING BY INVITATION

Defined Fecal Microbiota Transplantation for Clostridium Difficile Diarrhea

Baylor College of Medicine

NCT06639997 COMPLETED

Safety and Tolerability of AZD5148 in Japanese Participants

AstraZeneca

NCT07251127 COMPLETED

Study of Metronidazole Delayed-Release Capsules in Comparison With Immediate-Release Tablets (Flagyl) for Safety and Pharmacokinetics

Gateway Pharmaceutical LLC

NCT02830542 COMPLETED

SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence

Seres Therapeutics, Inc.

NCT04891965 COMPLETED

A Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI)

Adiso Therapeutics

NCT03827447 COMPLETED

Vancomycin for the Treatment of NAAT(+)/Toxin(-) C. Difficile

Medical College of Wisconsin

NCT02981316 COMPLETED

Treatment of Recurrent Clostridium Difficile Infection With RBX7455

Mayo Clinic

NCT03793686 TERMINATED

A Study of Safety of PBCLN-003 Following Antibiotic Therapy in Subjects With C.Difficile-associated Diarrhea

Prolacta Bioscience

NCT02865616 COMPLETED

MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI)

NuBiyota

NCT02423967 COMPLETED

Fresh Versus Frozen Stool for Fecal Transplant in Children

Mayo Clinic

NCT02052726 COMPLETED

A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine.

Pfizer

NCT02725437 COMPLETED

Clostridium Difficile Vaccine Safety, Tolerability, and Immunogenicity Study in Japanese Adults

Pfizer

NCT01551004 COMPLETED

Phase I Trial of a Single Dose of CRS3123

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02343328 TERMINATED

Placebo Controlled Study of Fecal Microbiota Transplant (FMT) for a First or Second Episode of C. Difficile Infection in Adults Using a Frozen Encapsulated Inoculum

Massachusetts General Hospital

NCT02991417 TERMINATED

Oral Vaccination Against Clostridium Difficile Infection

Simon M. Cutting

NCT02589964 TERMINATED

Probiotics in the Reduction of Antibiotic Associated Diarrhea

TriHealth Inc.

NCT02835105 COMPLETED

A Study of Ascending Single Doses of Surotomycin in Healthy Participants (MK-4261-008)

Merck Sharp & Dohme LLC

NCT02835118 COMPLETED

A Study of Ascending Multiple Doses of Oral Surotomycin in Healthy Participants (MK-4261-009)

Merck Sharp & Dohme LLC

NCT01914731 COMPLETED

Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum

Massachusetts General Hospital

NCT02106338 COMPLETED

Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123.

National Institute of Allergy and Infectious Diseases (NIAID)

NCT01296386 COMPLETED

An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84

Valneva Austria GmbH

NCT01822977 COMPLETED

The Impact of Proton Pump Inhibitors on the Fecal Microbiome

Mayo Clinic

NCT01704937 COMPLETED

Fecal Microbiota Transplant (FMT) for Relapsing C. Difficile Infection in Adults and Children Using a Frozen Inoculum

Massachusetts General Hospital

NCT01706367 COMPLETED

Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years

Pfizer

NCT02053181 COMPLETED

Study to Investigate the Pharmacokinetics and Safety of Cadazolid in Patients With Clostridium Difficile Infection

Actelion

NCT06794944 NOT YET RECRUITING

Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel Disease

Brigham and Women's Hospital

NCT04171817 COMPLETED

Animal-Assisted Visitation Program Chlorhexidine Trial

Johns Hopkins Bloomberg School of Public Health

NCT04090346 COMPLETED

Fecal Microbiota Transplant

Methodist Health System

NCT04003818 TERMINATED

Efficacy and Safety of Teicoplanin in CDAD

Sanofi

NCT02437591 COMPLETED

Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)

Astellas Pharma Europe Ltd.

NCT02254967 COMPLETED

A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population

Astellas Pharma Europe Ltd.

NCT01901276 COMPLETED

Effects of Gastric Acid on Colonic Microbiome

Daniel Freedberg, MD

NCT02996487 COMPLETED

Screening to Prophylax Against Clostridium Difficile Infection -

Corewell Health East

NCT03466502 COMPLETED

Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics

University of Nevada, Reno

NCT04000555 TERMINATED

Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)

University of South Florida

NCT03937999 TERMINATED

Bezlotoxumab as Secondary Prophylaxis for C. Difficile in High-risk Hospitalized Patients Exposed to Antibiotics.

Montefiore Medical Center

NCT01972932 TERMINATED

Study of Bio-K+® in the Reduction of the Risk of Clostridium Difficile Infection and Antibiotic Associated Diarrhea

Bio-K Plus International Inc.

NCT03880539 COMPLETED

Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection

University of Kansas Medical Center

NCT02692651 COMPLETED

A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections

University of Michigan

NCT01670149 COMPLETED

Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea

University of Nottingham

NCT03388268 COMPLETED

TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment

Washington University School of Medicine

NCT03200093 TERMINATED

Oral Vancomycin for Preventing Clostridium Difficile Recurrence

Rochester General Hospital

NCT04241744 WITHDRAWN

Prospective Trial of Oral Vancomycin Therapy vs. Placebo for Prevention of CDI

Creighton University

NCT01775397 TERMINATED

A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System

Astellas Pharma Europe Ltd.

NCT02057198 COMPLETED

Impact of Oral Antibiotic Treatment on C. Difficile

Duke University

NCT02464306 WITHDRAWN

Fidaxomicin Versus Standard of Care Therapy in Solid Organ Transplant Recipients With Clostridium Difficile Infection

University of Colorado, Denver

NCT03592082 WITHDRAWN

Use of Bismuth Subsalicylate in Clostridium Difficile Colitis

Bassett Healthcare

NCT02951702 COMPLETED

Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics

St. Luke's Hospital, Chesterfield, Missouri

NCT01818141 COMPLETED

Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin

Hartford Hospital

NCT02200328 TERMINATED

Efficacy of Metronidazole Prophylaxis Against Clostridium Difficile-Associated Diarrhea in High Risk Adult Patients

Alison Schneider

NCT02355938 TERMINATED

Use Of Oral Fidaxomicin Vs. Oral Vancomycin For Clostridium Difficile Infection In Patients With Spinal Cord Injury

Baylor College of Medicine

NCT01552668 WITHDRAWN

Fidaxomicin to Prevent Clostridium Difficile Colonization

Washington University School of Medicine

Full C. difficile Pipeline

Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only